Riskpilot← Back to searchSign inGet full accessJELØY APOTEK AS
ASActiveOrg 926959999Glassverket 2, 1515 MossRetail sale of pharmaceutical products · NACE 4773Est. 20218 employees
Revenue 2025
NOK 20M
-9% vs 2024
EBITDA margin
6.5%
-12% vs 2024
Equity ratio
24.9%
Financial strength
Net profit 2025
NOK 872K
-13% vs 2024
| Revenue | NOK 20M | -9% |
| EBITDA | NOK 1,3M | -12% |
| Net profit | NOK 872K | -13% |
| Total assets | NOK 3,7M | -24% |
| Equity | NOK 915K | +2033% |
| Employees | 8 | — |
Legal name
JELØY APOTEK AS
Org number
926959999
Legal form
Aksjeselskap
NACE code
4773 · Retail sale of pharmaceutical products
Founded
19. april 2021
Share capital
NOK 42 900
Employees
8 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Muhammad sadiq
Company purpose
Å eie og drive apotek og relaterte aktiviteter.
Address
Glassverket 2, 1515 Moss
Phone
+4769701414
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 650 | 10 485 | 17 014 | 21 871 | 19 983 |
| Staff expenses | −167 | −1 301 | −2 233 | −2 731 | −2 745 |
| EBITDA | −126 | 708 | 1 029 | 1 477 | 1 301 |
| Depreciation & amort. | −12 | −124 | −124 | −133 | −135 |
| EBIT | −138 | 584 | 905 | 1 344 | 1 166 |
| Net financials | 0 | −50 | −59 | −58 | −47 |
| Profit before tax | −138 | 534 | 846 | 1 285 | 1 120 |
| Tax | −30 | 117 | 186 | 284 | 248 |
| Net profit | −108 | 416 | 659 | 1 001 | 872 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 3 847 | 3 303 | 7 463 | 4 835 | 3 678 |
| Equity | 492 | 908 | 268 | 43 | 915 |
| Long-term debt | 1 000 | 914 | 772 | 625 | 0 |
| Short-term debt | 2 355 | 1 481 | 6 424 | 4 167 | 2 299 |
| Total debt | 3 355 | 2 395 | 7 196 | 4 792 | 2 763 |
EBITDA margin
6.5%
This company
15.8%
Market median
-59% vs market
20212025
Equity ratio
24.9%
This company
38.2%
Market median
-35% vs market
20212025
Return on equity
95.3%
This company
18.4%
Market median
+418% vs market
20212025
Net profit margin
4.4%
This company
8.1%
Market median
-46% vs market
20212025
Asset turnover
5.43×
This company
1.12×
Market median
+385% vs market
20212025
Debt / equity
3.02×
This company
0.62×
Market median
-387% vs market
20212025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-27 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
KK Chief Executive Officer | Chief Executive Officer | 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Deputy Chairman | 2025 | |
| Chairman | 2025 | |
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 31% | 31% | 2024 | |
| Company | 26% | 26% | 2024 | |
| Company | 25% | 25% | 2024 | |
| Company | 18% | 18% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Pharma Care Invest As
JELØY APOTEK AS Board members of JELØY APOTEK AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Komal Khan | Chief Executive Officer | 0 companies |
| Tariq Ejaz | Deputy Chairman | 0 companies |
| Muhammad Sadiq | Chairman | 0 companies |
| Malik Mumtaz Hussain Taqi | Board of Directors | 0 companies |
| Johan Fredrik Balstad | Board of Directors | 0 companies |